Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections
Unknown status
Vicuron Pharmaceuticals
Phase 2
2001-02-01
This is a study to evaluate a new medication dosed once a week in the treatment of bacterial
infections in the blood from intravenous catheters (CR-BSI). The primary objective is to
evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI
relative to a standard of care treatment, vancomycin.
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
Completed
Pfizer
Phase 1
2008-09-01
Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1
gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be
measured at different time points. Safety labs will also be checked on a regular basis to
assess the safety of dalbavancin.
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Completed
Durata Therapeutics Inc., an affiliate of Allergan plc
Phase 3
2011-03-01
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy)
of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral
linezolid) for the treatment of patients with a suspected or proven gram-positive bacterial
skin or skin structure infection.
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Completed
Durata Therapeutics Inc., an affiliate of Allergan plc
Phase 3
2011-07-01
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy)
of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral
linezolid) for the treatment of patients with a suspected or proved gram-positive bacterial
skin or skin structure infections.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
